By Katherine Hamilton
ScPharmaceuticals shares fell Wednesday morning after it disclosed it might have to delay submitting a new product to the Food and Drug Administration.
Shares were down 8% to $3.25 in recent trading. The stock is down about 61.3% this year.
One lot of the company's SCP-111 combination product showed varying results in shelf-life testing, which is the amount of time a product can maintain an acceptable level of quality, the company said in a Wednesday filing.
SCP-111 is designed to treat fluid overload and retention.
The variation could delay when the company submits a supplemental new drug application for the product with the FDA.
ScPharmaceuticals was planning to submit the product for approval in January, but may delay until later in 2025, the company said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 11, 2024 10:24 ET (15:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。